Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)Defense World · Oct 17, 2026
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDAGlobeNewsWire · Oct 6, 2026
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader WebinarGlobeNewsWire · Oct 1, 2026
Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)Defense World · Sep 16, 2026
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 3, 2026
60 Degrees Pharmaceuticals Announces Second Quarter 2026 ResultsGlobeNewsWire · Aug 14, 202660 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.74 | -$0.90 | Miss |
| May 15, 2026 | -$0.76 | -$1.28 | Miss |
| Mar 26, 2026 | -$2.28 | -$1.69 | Beat |
| Nov 13, 2025 | -$1.84 | -$2.64 | Miss |
| Aug 12, 2025 | -$4.96 | -$5.00 | Miss |
| May 15, 2025 | -$5.24 | -$6.24 | Miss |